Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091169 · ClinicalTrials.gov registry record · Phase 3
Levocarnitine in Treating Fatigue in Cancer Patients
A Phase 3 study of Unspecified Adult Solid Tumor, Protocol Specific and Fatigue, sponsored by ECOG-ACRIN Cancer Research Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 376
- Enrollment target
- 20
- Study locations
NCT00091169 is a Phase 3 study of Unspecified Adult Solid Tumor, Protocol Specific and Fatigue that has completed, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 376 participants, below the 497-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT00091169, a Phase 3 study of Unspecified Adult Solid Tumor, Protocol Specific and Fatigue, has completed, sponsored by ECOG-ACRIN Cancer Research Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 376 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Levocarnitine may help improve energy levels in cancer patients. PURPOSE: This randomized phase III trial is studying how well levocarnitine works compared to a placebo in treating fatigue in cancer patients.
Conditions Studied
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT levocarnitine
Study Locations (20)
Illinois
- Rush-Copley Cancer Care Center - Aurora
- St. Joseph Medical Center - Bloomington
- Graham Hospital - Canton
- Memorial Hospital - Carthage
- Eureka Community Hospital - Eureka
- Evanston Northwestern Healthcare - Evanston Hospital - Evanston
- Galesburg Clinic, PC - Galesburg
- Galesburg Cottage Hospital - Galesburg
- Mason District Hospital - Havana
- Hopedale Medical Complex - Hopedale
- Joliet Oncology-Hematology Associates, Limited - West - Joliet
- McDonough District Hospital - Macomb
- BroMenn Regional Medical Center - Normal
- Community Cancer Center - Normal
California
- Veterans Affairs Medical Center - Palo Alto - Palo Alto
- Stanford Comprehensive Cancer Center - Stanford - Stanford
Connecticut
- Praxair Cancer Center at Danbury Hospital - Danbury
- Manchester Memorial Hospital - Manchester
Florida
- Lynn Regional Cancer Center at Boca Raton Community Hospital - Main Center - Boca Raton
- Baptist Cancer Institute - Jacksonville - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2005-12-16 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091169
The ClinicalTrials.gov registry entry for NCT00091169 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 497-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (24% lower). The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00091169 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Illinois, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00091169 about?
NCT00091169 is a clinical study titled "Levocarnitine in Treating Fatigue in Cancer Patients". RATIONALE: Levocarnitine may help improve energy levels in cancer patients. PURPOSE: This randomized phase III trial is studying how well levocarnitine works compared to a placebo in treating fatigue in cancer patients.
What is the current status of trial NCT00091169?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 376 participants. The study started on 2005-12-16. Estimated completion is 2011-05.
What conditions does trial NCT00091169 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Fatigue.
What interventions are being tested in trial NCT00091169?
The interventions under investigation include: placebo (OTHER), levocarnitine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00091169?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00091169 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
COMPLETED · Phase 3
-
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
COMPLETED · Phase 3
-
Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
COMPLETED · Phase 3
-
Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer
COMPLETED · Phase 3
-
(Valerian) for Improving Sleep in Patients With Cancer Receiving Adjuvant Therapy
COMPLETED · Phase 3
-
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.